Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at two types of imaging tests, called PSMA PET and FDG PET, to better understand advanced prostate cancer. By using these tests, researchers hope to learn more about how tumors behave at different stages of the disease and during treatment. This information may help doctors choose the best treatments for patients in the future and monitor how well those treatments are working.

To participate in this study, men aged 18 and older with confirmed advanced prostate cancer may be eligible, especially those with high-risk disease that has spread. Participants must be willing to undergo the imaging tests and continue receiving care from doctors at the Princess Margaret Cancer Center. It's important to note that the study is not yet recruiting participants, and there are specific health conditions that could prevent someone from joining, such as having difficulty with the imaging tests or other serious health issues. Overall, this trial aims to improve understanding and treatment of advanced prostate cancer, which could benefit future patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male, age ≥ 18 years
• • Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
• • Poor risk patients with mCSPC at study enrollment
• • De novo or recurrent high volume mCSPC as per conventional imaging (CT chest abdomen pelvis, or MRI, plus bone scan) prior to starting ADT and ARPI
• • High or low volume mCSPC plus PSA ≥4.0 after 6-8 months of initiating ADT
• • Willing to undergo study PET scans and remain under the care of medical oncology, radiation oncology or urology physician at Princess Margaret Cancer Center.
• • No prior PSMA or FDG PET imaging within the last 60 days at each specified time point on study
• • Patients enrolled in clinical trials are eligible if they satisfy all other criteria of eligibility
• Exclusion Criteria:
• • Under a randomized-controlled trial with unknown allocation of systemic therapy
• • Inability to undergo or successfully complete PSMA PET and FDG PET imaging exams
• • Unable to provide written consent by patient and their legal representatives
• * In the opinion of the treating physician:
• • conditions which would significantly impair the patient's ability to comply with study procedures and follow up
• • Significant uncontrolled comorbidity, which may negatively impact the safety or interpretability of study PET imaging
• • another active malignancy
• • patient on dialysis
• • another radioisotope or investigational systemic agent within 5 half-lives prior to PET imaging